Health'Breakthrough' mRNA cancer drug curbs melanoma recurrence in large trial

Merck and Moderna said a personalised cancer treatment reduced the recurrence of melanoma tumours in a late-stage trial. Experts called the result a breakthrough, marking the first positive outcome for an mRNA cancer drug in a large, late-stage clinical study.